Literature DB >> 30273599

Enteroviral Infection Leads to Transactive Response DNA-Binding Protein 43 Pathology in Vivo.

Yuan Chao Xue1, Chelsea M Ruller2, Gabriel Fung1, Yasir Mohamud1, Haoyu Deng3, Huitao Liu4, Jingchun Zhang1, Ralph Feuer5, Honglin Luo6.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that primarily affects motor neurons in the cerebral cortex, brainstem, and spinal cord, leading to progressive paralysis and eventual death. Approximately 95% of all ALS cases are sporadic without known causes. Enteroviruses have been suspected to play a role in ALS because of their ability to target motor neurons and to cause muscle weakness and paralysis. In vitro enteroviral infection results in cytoplasmic aggregation and cleavage of transactive response DNA binding protein-43, a pathologic hallmark of ALS. However, whether enteroviral infection can induce ALS-like pathologies in vivo remains to be characterized. In this study, neonatal BALB/C mice were intracranially inoculated with either a recombinant coxsackievirus B3 expressing enhanced green fluorescent protein or mock-infected for 2, 5, 10, 30, and 90 days. Histologic and immunohistochemical analysis of brain tissues demonstrated sustained inflammation (microglia and astrogliosis) and lesions in multiple regions of the brain (hippocampus, cerebral cortex, striatum, olfactory bulb, and putamen) in parallel with virus detection as early as 2 days for up to 90 days after infection. Most notably, ALS-like pathologies, including cytoplasmic mislocalization of transactive response DNA binding protein-43, p62-, and ubiquitin-positive inclusions, were observed in the areas of infection. These data provide the first pathologic evidence to support a possible link between enteroviral infection and ALS.
Copyright © 2018 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30273599     DOI: 10.1016/j.ajpath.2018.08.013

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  7 in total

1.  cGAS and DDX41-STING mediated intrinsic immunity spreads intercellularly to promote neuroinflammation in SOD1 ALS model.

Authors:  Hong Yien Tan; Yean Kong Yong; Yuan Chao Xue; Huitao Liu; Tomomi Furihata; Esaki Muthu Shankar; Chen Seng Ng
Journal:  iScience       Date:  2022-05-13

Review 2.  Neuromuscular Complications of SARS-CoV-2 and Other Viral Infections.

Authors:  Sarah Jacob; Ronak Kapadia; Tyler Soule; Honglin Luo; Kerri L Schellenberg; Renée N Douville; Gerald Pfeffer
Journal:  Front Neurol       Date:  2022-06-24       Impact factor: 4.086

3.  MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer.

Authors:  Huitao Liu; Yuan Chao Xue; Haoyu Deng; Yasir Mohamud; Chen Seng Ng; Axel Chu; Chinten James Lim; William W Lockwood; William W G Jia; Honglin Luo
Journal:  Mol Ther Oncolytics       Date:  2020-01-21       Impact factor: 7.200

4.  Antiviral Immune Response as a Trigger of FUS Proteinopathy in Amyotrophic Lateral Sclerosis.

Authors:  Tatyana A Shelkovnikova; Haiyan An; Lucy Skelt; John S Tregoning; Ian R Humphreys; Vladimir L Buchman
Journal:  Cell Rep       Date:  2019-12-24       Impact factor: 9.995

5.  Sublethal enteroviral infection exacerbates disease progression in an ALS mouse model.

Authors:  Yuan Chao Xue; Huitao Liu; Yasir Mohamud; Amirhossein Bahreyni; Jingchun Zhang; Neil R Cashman; Honglin Luo
Journal:  J Neuroinflammation       Date:  2022-01-12       Impact factor: 8.322

Review 6.  Viruses in neurodegenerative diseases: More than just suspects in crimes.

Authors:  Pascal Leblanc; Ina Maja Vorberg
Journal:  PLoS Pathog       Date:  2022-08-04       Impact factor: 7.464

7.  Identification of viral-mediated pathogenic mechanisms in neurodegenerative diseases using network-based approaches.

Authors:  Anna Onisiforou; George M Spyrou
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.